DE2840039C2 - - Google Patents

Info

Publication number
DE2840039C2
DE2840039C2 DE2840039A DE2840039A DE2840039C2 DE 2840039 C2 DE2840039 C2 DE 2840039C2 DE 2840039 A DE2840039 A DE 2840039A DE 2840039 A DE2840039 A DE 2840039A DE 2840039 C2 DE2840039 C2 DE 2840039C2
Authority
DE
Germany
Prior art keywords
cells
antibody
animal
tumor
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2840039A
Other languages
German (de)
English (en)
Other versions
DE2840039A1 (de
DE2840039C3 (de
Inventor
Hilary Prof. Wynnewood Pa. Us Koprowski
Carlo M. Prof. Philadelphia Pa. Us Croce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of DE2840039A1 publication Critical patent/DE2840039A1/de
Publication of DE2840039C2 publication Critical patent/DE2840039C2/de
Application granted granted Critical
Publication of DE2840039C3 publication Critical patent/DE2840039C3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE2840039A 1978-04-28 1978-09-14 Verfahren zur Erzeugung von Tumor-Antikörpern Expired - Lifetime DE2840039C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/901,102 US4172124A (en) 1978-04-28 1978-04-28 Method of producing tumor antibodies

Publications (3)

Publication Number Publication Date
DE2840039A1 DE2840039A1 (de) 1979-11-08
DE2840039C2 true DE2840039C2 (enExample) 1988-06-30
DE2840039C3 DE2840039C3 (de) 1994-04-14

Family

ID=25413599

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2840039A Expired - Lifetime DE2840039C3 (de) 1978-04-28 1978-09-14 Verfahren zur Erzeugung von Tumor-Antikörpern

Country Status (4)

Country Link
US (1) US4172124A (enExample)
JP (1) JPS5845407B2 (enExample)
CA (1) CA1103156A (enExample)
DE (1) DE2840039C3 (enExample)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486538A (en) * 1978-07-07 1984-12-04 Samuel Bogoch Detection of malignant tumor cells
DE2836362A1 (de) * 1978-08-19 1980-03-06 Behringwerke Ag Diagnostisches mittel
CA1142466A (en) * 1979-01-09 1983-03-08 Cesar Milstein Cell lines
US4657760A (en) * 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4515894A (en) * 1979-03-20 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to human T cells
US4363799A (en) * 1979-03-20 1982-12-14 Ortho Pharmaceutical Corporation Monoclonal antibody to human T cells, and methods for preparing same
US4680383A (en) * 1979-03-20 1987-07-14 Ortho Pharmaceutical Monoclonal antibody to human T cells
US4652447A (en) * 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
US4658019A (en) * 1979-04-26 1987-04-14 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells
US4515893A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4654210A (en) * 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4658020A (en) * 1979-04-26 1987-04-14 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells
US4515895A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to human helper T cells
US4361549A (en) * 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4364932A (en) * 1979-09-18 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
US4349528A (en) * 1979-11-21 1982-09-14 The Wistar Institute Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
US4709015A (en) * 1979-12-04 1987-11-24 Ortho Pharmaceutical Corporation Monoclonal antibody to human suppressor T cells
US4806629A (en) * 1979-12-04 1989-02-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US4828995A (en) * 1979-12-04 1989-05-09 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to a human thymocyte antigen, antibody, and methods
US4364935A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
US4361550A (en) * 1979-12-04 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
US4725543A (en) * 1979-12-04 1988-02-16 Kung Patrick C Hybrid cell line for producing complement-fixing monoclonal antibody to human suppressor T cells, antibody and methods
USRE33405E (en) * 1979-12-28 1990-10-23 Research Corporation Technologies, Inc. Purified human prostate antigen
JPS57500169A (enExample) * 1979-12-28 1982-01-28
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4396601A (en) * 1980-03-26 1983-08-02 The Regents Of The University Of Calif. Gene transfer in intact mammals
US5204095A (en) * 1980-04-09 1993-04-20 National Research Development Corporation Monoclonal antibodies against hepatitis B virus
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4510244A (en) * 1980-04-17 1985-04-09 The Board Of Trustees Of The Leland Stanford Jr. University Cell labeling with antigen-coupled microspheres
US4668629A (en) * 1980-07-18 1987-05-26 The Board Of Trustees Of Leland Stanford Jr. University Human hybridomas, precursors and products
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US6713619B1 (en) 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4626507A (en) * 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
EP0060871B1 (en) * 1980-09-25 1985-10-23 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line
WO1982001773A1 (en) * 1980-11-07 1982-05-27 Secher David S Assay for interferon
US4831124A (en) * 1980-12-10 1989-05-16 Research Corporation Technologies Recombinant cDNA construction method and hybrid nucleotides useful in cloning
JPS5823847B2 (ja) * 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
DE3235924T1 (de) * 1981-03-06 1983-05-05 Celltech Ltd., Slough, Berkshire Monoklonaler antikoerper
US4680258A (en) * 1981-03-24 1987-07-14 Sloan-Kettering Institute For Cancer Research Process for sex determination in man by use of monoclonal antibodies to the H-Y antigen
US4451570A (en) * 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
IL62879A (en) * 1981-05-15 1985-09-29 Chaya Moroz Monoclonal antibodies,clones producing them,preparation of such antibodies and clones and cytotoxic and immunoassay using such antibodies
US4471057A (en) * 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4650756A (en) * 1981-08-31 1987-03-17 Sloan Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human renal cancer
JPH06157346A (ja) * 1981-09-08 1994-06-03 Suntory Ltd 選択性制癌剤
US4816249A (en) * 1981-11-17 1989-03-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
EP0095502A4 (en) * 1981-12-08 1987-01-20 Univ South Carolina MONOCLONIC HUMAN ANTIBODIES OR LYMPHOCINS IN CELL SEPARATION OR IN DIAGNOSIS OF BREAST CANCER.
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4455296A (en) * 1982-02-02 1984-06-19 Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
EP0087898A1 (en) * 1982-02-22 1983-09-07 Cancer Research Campaign Technology Limited Antibodies and antigens useful in the diagnosis and treatment of cancer
US4487833A (en) * 1982-03-01 1984-12-11 The General Hospital Corporation Method of preparing hybridomas and of purifying immunogenic materials
US4792601A (en) * 1982-03-01 1988-12-20 The General Hospital Corporation Monoclonal antibody to mullerian inhibiting substance
US4618585A (en) * 1982-03-18 1986-10-21 Board Of Regents, The University Of Texas System Hybridoma cell lines producing monoclonal antibodies directed against cervical cancer cells
DE3211356A1 (de) * 1982-03-27 1983-09-29 Behringwerke Ag, 3550 Marburg Zell-hybrid, verfahren zu seiner herstellung sowie seine verwendung
CA1209907A (en) * 1982-04-12 1986-08-19 Richard M. Bartholomew Method of affinity purification employing monoclonal antibodies
DE3245665A1 (de) * 1982-05-04 1983-11-10 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung permanenter tierischer und humaner zellinien und deren verwendung
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4514498A (en) * 1982-05-26 1985-04-30 The Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Treponema
US4987079A (en) * 1982-07-06 1991-01-22 Wilbur D. Smith Composition and method for in vitro cell culture
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4529700A (en) * 1982-08-20 1985-07-16 University Of Miami Hybridoma cells secreting a monoclonal antibody specific for 5-bromo and 5-iodoeoxyuridine and reagents for measuring cellular proliferation
US4596771A (en) * 1982-09-27 1986-06-24 Research Corporation Monoclonal antibodies to vitamin B-6 and immunossay method
US4465776A (en) * 1982-09-27 1984-08-14 Research Corporation Monoclonal antibodies to vitamin B6 and immunoassay method
US4689299A (en) * 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
CA1262238A (en) 1982-09-30 1989-10-10 Richard Insel Human monoclonal antibodies against bacterial toxins
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
CA1254846A (en) * 1982-11-30 1989-05-30 Anthony Albino Monoclonal antibodies against melanocytes and melanomas
GB2131830A (en) * 1982-12-10 1984-06-27 Ludwig Inst Cancer Res Monoclonal antibody for use against breast cancer
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4504586A (en) * 1983-02-03 1985-03-12 Amgen Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
JPS59155259A (ja) * 1983-02-23 1984-09-04 株式会社　ミドリ十字 腫瘍細胞除去用炉過器
CA1215331A (en) * 1983-03-04 1986-12-16 Tsann M. Chu Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4591572A (en) * 1983-04-01 1986-05-27 Sloan-Kettering Institute For Cancer Research Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
US4562160A (en) * 1983-04-01 1985-12-31 Sloan-Kettering Institute Melanoma tumor antigen and autologous antibody
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4569788A (en) * 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer
US4652522A (en) * 1983-07-05 1987-03-24 The University Of Pennsylvania Continuous lymphocyte cell lines, their production and use
US4707442A (en) * 1983-10-24 1987-11-17 Board Of Regents, The University Of Texas System Hybrid cell line producing monoclonal antibody cytolytic to Trichomonas vaginalis
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US4731237A (en) * 1983-11-07 1988-03-15 The Wistar Institute Immune response to virus induced by anti-idiotype antibodies
US4670382A (en) * 1983-12-02 1987-06-02 Temple University--of the Commonwealth System of Higher Education Monoclonal antibody to Candida albicans cytoplasmic antigens and methods of preparing same
US5348880A (en) * 1984-01-31 1994-09-20 Akzo N.V. Tumor associated monoclonal antibody 81AV/78
US4997762A (en) * 1984-01-31 1991-03-05 Akzo N.V. Tumor associated monocoloal antibodies derived from human B-cell line
US5495002A (en) * 1984-01-31 1996-02-27 Akzo N.V. Tumor associated monoclonal antibody 123AV16
US5474755A (en) * 1984-01-31 1995-12-12 Akzo Nobel N.V. Tumor associated monoclonal antibodies
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
JPS60190721A (ja) * 1984-03-12 1985-09-28 Kyowa Hakko Kogyo Co Ltd 抗腫瘍特異的単クロ−ン性抗体の製造法
US4683200A (en) * 1984-05-17 1987-07-28 Setsuo Hirohashi Monoclonal antibody to human cancer antigen and method for producing same
US4863729A (en) * 1984-06-20 1989-09-05 Linus Pauling Institute Of Science And Medicine Method for preparing a macromolecular monoclonal antibody composition
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
JPS63501096A (ja) * 1984-10-29 1988-04-21 エクス　インコ−ポレ−テツド 小型分子の免疫測定法
ZA858371B (en) * 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas
IL76877A (en) * 1984-11-02 1991-11-21 Oncogen Diagnostic method for the determination of human non-small cell lung carcinomas employing novel monoclonal antibodies and compositions containing said antibodies
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US4628032A (en) * 1984-12-05 1986-12-09 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cytoplasmic antigen
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
US4814275A (en) * 1985-05-13 1989-03-21 E.I. Dupont De Nemours And Company Monoclonal hybridoma antibody specific for a human epithelial antigen
US5275812A (en) * 1985-06-07 1994-01-04 The General Hospital Corporation Method of treatment for myocardial infarction
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4599229A (en) * 1985-09-09 1986-07-08 International Minerals & Chemical Corp. Method of promoting animal growth using antibodies against somatostatin
US5009995A (en) * 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
NZ224422A (en) * 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5157113A (en) * 1987-08-10 1992-10-20 Miles Inc. Removal of nucleic acids from monoclonal antibody preparations
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5344870A (en) * 1987-12-02 1994-09-06 Alberta Research Council Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5244801A (en) * 1989-12-28 1993-09-14 Martin Tobi Process for producing monoclonal antibodies which specifically bind to benign colonic adenomatous polyps of human origin and hybridomas and monoclonal antibodies produced by said process
IL103758A (en) 1991-12-13 1998-07-15 Akzo Nv Tumor specific monoclonal antibodies
US7326535B2 (en) 1993-09-15 2008-02-05 Ortho Diagnostic Systems Inc. Immunoreactive peptides from Epstein-Barr virus
US7060283B1 (en) 1992-09-15 2006-06-13 Ortho Diagnostic Systems, Inc. Immunoreactive peptides from Epstein-Barr virus
US5545527A (en) * 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US6506553B1 (en) 1995-03-30 2003-01-14 Ortho Diagnostics Systems, Inc. Method for diagnosis of Epstein-Barr virus associated disease
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US5965521A (en) * 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7252821B2 (en) * 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20060210474A1 (en) * 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2003904154A0 (en) * 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
ATE373089T1 (de) * 2001-07-18 2007-09-15 Bionomics Ltd Mutationen in ionenkanälen
EP1434482B9 (en) * 2001-10-11 2007-11-28 Marical, Inc. Methods for growing and imprinting fish using an odorant
ES2646792T3 (es) 2002-01-25 2017-12-18 Novo Nordisk A/S Anticuerpos monoclonales contra bucles extracelulares de C5aR
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
AU2003901425A0 (en) * 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
MXPA06000176A (es) 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
CA2559554A1 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
CA2521973C (en) * 2004-09-29 2013-12-10 Tir Systems Ltd. System and method for controlling luminaires
KR20070094909A (ko) 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
CA2612180A1 (en) * 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
CN101365714A (zh) 2005-07-01 2009-02-11 福赛特儿童口腔医院 结核抗原的检测分析及疫苗
JP5489459B2 (ja) 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
CA2621441C (en) 2005-09-12 2014-05-20 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
ES2531052T3 (es) 2006-01-05 2015-03-10 Univ Ohio State Res Found Métodos y composiciones basados en microARN para el diagnóstico de cánceres de mama
ES2554531T3 (es) 2006-01-05 2015-12-21 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
JP2009537536A (ja) * 2006-05-15 2009-10-29 ユニヴァーシティ・オヴ・ケンタッキー 眼の血管形成および黄斑変性に対するＴｏｌｌ様受容体（ＴＬＲ）の刺激
EP2436786B1 (en) * 2006-07-13 2014-04-16 The Ohio State University Research Foundation MIR-10a for diagnosing poor survival prognosis colon adenocarcinoma.
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
ATE534752T1 (de) * 2006-09-19 2011-12-15 Univ Ohio State Res Found Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
US8034560B2 (en) 2007-01-31 2011-10-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
ES2537349T3 (es) 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
JP5480132B2 (ja) 2007-06-15 2014-04-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｄｒｏｓｈａ媒介性のマイクロｒｎａプロセッシングを標的するための癌原性ａｌｌ−１融合タンパク質
US8367632B2 (en) 2007-07-31 2013-02-05 Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
CN101835902B (zh) 2007-08-03 2014-03-26 俄亥俄州立大学研究基金会 编码ncrna的超保守区域
AU2008288806B2 (en) 2007-08-22 2014-11-27 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of EphA7 and Erk phosphorylation in human acute leukemias
EP2201112A4 (en) 2007-10-26 2011-02-02 Univ Ohio State Res Found METHOD FOR IDENTIFYING FHIT INTERACTION AND USE
US8815237B2 (en) 2007-12-05 2014-08-26 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
JP5511684B2 (ja) 2008-01-11 2014-06-04 アドヘロン セラピューティクス，インコーポレイテッド 炎症性関節障害を治療するためのカドヘリン−１１ｅｃｌドメインアンタゴニスト
EP2307028B1 (en) 2008-06-11 2013-10-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
WO2010040029A1 (en) 2008-10-02 2010-04-08 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
ES2631507T3 (es) 2008-10-29 2017-08-31 China Synthetic Rubber Corporation Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
CA2758967A1 (en) 2009-04-16 2010-10-21 Forsyth Dental Infirmary For Children New methods of making an antibody and compositions thereof
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
WO2011068870A2 (en) 2009-12-01 2011-06-09 President And Fellows Of Harvard College Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
US20110217297A1 (en) 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
AU2011279044B2 (en) 2010-07-15 2013-12-19 Adheron Therapeutics, Inc. Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
US10758619B2 (en) 2010-11-15 2020-09-01 The Ohio State University Controlled release mucoadhesive systems
EP2640425A2 (en) 2010-11-18 2013-09-25 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
HK1197273A1 (en) 2011-10-14 2015-01-09 The Ohio State University Methods and materials related to ovarian cancer
JP2015501843A (ja) 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション ｍｉＲ−２１およびｍｉＲ−２９ａ、エキソソーム阻害、およびがん転移に関する方法および組成物
CN104685065B (zh) 2012-01-20 2017-02-22 俄亥俄州立大学 浸润性和预后的乳腺癌生物标志物标签
WO2013134577A2 (en) 2012-03-08 2013-09-12 Detectogen, Inc. Leishmaniasis antigen detection assays and vaccines
WO2014058915A2 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US10024844B2 (en) 2012-12-20 2018-07-17 Hospital For Special Surgery Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
JP6615100B2 (ja) 2013-09-24 2019-12-04 ザ ファインスタイン インスティチュート フォー メディカル リサーチ 低温誘導性ｒｎａ結合タンパク質活性を阻害するペプチド
WO2015048531A1 (en) 2013-09-26 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Inhibition of sgk1 in the treatment of heart conditions
EP3207937A1 (en) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland A method of treating or preventing sepsis
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
US10562975B2 (en) 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
WO2019005503A1 (en) 2017-06-29 2019-01-03 Rutgers, The State University Of New Jersey COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3
WO2022157336A1 (en) 2021-01-22 2022-07-28 Royal College Of Surgeons In Ireland Treatment of coronavirus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE440697B (sv) * 1972-07-10 1985-08-12 Bonnierfoeretagen Ab Forfarande for diagnosticering av cancer genom bestemning av nervaron av till cancer knutet polypeptidantigen (capa)

Also Published As

Publication number Publication date
US4172124A (en) 1979-10-23
JPS5845407B2 (ja) 1983-10-08
DE2840039A1 (de) 1979-11-08
DE2840039C3 (de) 1994-04-14
CA1103156A (en) 1981-06-16
JPS54143513A (en) 1979-11-08

Similar Documents

Publication Publication Date Title
DE2840039C2 (enExample)
DE3586440T2 (de) Zur diagnose von menschlichem magen- oder brustkrebs zu verwendender monoklonaler antikoerper.
DE3783277T2 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
DE69229254T2 (de) Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
DE69518919T2 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
DE69327620T2 (de) Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
EP0260610B1 (de) Monoklonale Antikörper gegen humanen Tumonekrosefaktor (TNF) und deren Verwendung
DE69330643T2 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
EP0586445B1 (de) Monoklonale antikörper gegen c-kit
DE69434097T2 (de) Apoptose induzierender monoklonaler antikörper
DE69130702T2 (de) Geflügelspezifischen immunglobulin g produzierende hybridomas
DE3650032T2 (de) Anticytomegaloviraler menschlicher monoklonaler antikörper und dessen herstellung.
WO1991017248A1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DE3889062T2 (de) Monoklonaler Antikörper gegen humanen BCDF.
DE3144181A1 (de) "human-myelomazell-linie und verfahren zur herstellung einer hybridzell-linie"
EP0584715A2 (de) Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper
DE69221845T2 (de) Monoklonale Antikörper gegen humanes IgE
CH683526A5 (de) Zellinie für die Herstellung von Antikörper bildenden Hybridomen, Verfahren zur Herstellung einer menschlichen Zellinie und Antikörper produzierendes Hybridom.
DE69434024T2 (de) Auf humanen cortikalen thymozyten exprimierte oberflächenproteine und ihre verwendung
DE69222909T2 (de) Monoklonaler Antikörper gegen ein Synaptophysin
DE3490527C2 (enExample)
DE19500723A1 (de) Gen oder Genfragment eines Antikörpers, der krebsspezifisches Mucin erkennt
DE3785795T2 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
DE3413339A1 (de) Gegen pilze der gattung candida gerichtete antikoerper
EP0090343A2 (de) Zell-Hybrid, Verfahren zu seiner Herstellung sowie seine Verwendung

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8305 Restricted maintenance of patent after opposition
D4 Patent maintained restricted